Cargando…

Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients

Background. Mortality for cryptococcal meningitis remains significant, in spite of available treatment. Resistance to first-line maintenance therapy, particularly fluconazole, has been reported. Methods. A retrospective chart review was performed on immunocompromised patients with cryptococcal menin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasri, Hashem, Kabbani, Sarah, Bou Alwan, Melhim, Wang, Yun F., Rebolledo, Paulina A., Kraft, Colleen S., Nguyen, Minh L., Anderson, Albert M., Rouphael, Nadine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943554/ https://www.ncbi.nlm.nih.gov/pubmed/27419153 http://dx.doi.org/10.1093/ofid/ofw076

Ejemplares similares

Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model
por: Chesdachai, Supavit, et al.
Publicado: (2019)

Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis
por: Mpoza, Edward, et al.
Publicado: (2017)

Evaluation of a Cryptococcal Antigen Lateral Flow Assay and Cryptococcal Antigen Positivity at a Large Public Hospital in Atlanta, Georgia
por: Harrington, Kristin R V, et al.
Publicado: (2021)

Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation
por: Rhein, Joshua, et al.
Publicado: (2018)

Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective Cohort
por: Tugume, Lillian, et al.
Publicado: (2022)

Failure of Early Mycological Clearance in HIV-Negative Cryptococcal Meningitis
por: Su, Zhihui, et al.
Publicado: (2023)

Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018)

High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
por: Zhao, Hua-Zhen, et al.
Publicado: (2018)

Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
por: Stone, Neil R.H., et al.
Publicado: (2019)

Cerebral Oximetry for Detecting High-mortality Risk Patients with Cryptococcal Meningitis
por: Diehl, John W, et al.
Publicado: (2018)

Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and Outcomes
por: Pastick, Katelyn A, et al.
Publicado: (2019)

Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis
por: Chesdachai, Supavit, et al.
Publicado: (2020)

Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality
por: Letang, Emilio, et al.
Publicado: (2015)

Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis
por: Schutz, Charlotte, et al.
Publicado: (2017)

88462 Fluconazole distribution in CNS and gynecological tissues in HIV-related cryptococcal meningitis decedents
por: Nicol, Melanie R., et al.
Publicado: (2021)

Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal Meningitis
por: Rhein, Joshua, et al.
Publicado: (2014)

Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis
por: Rolfes, Melissa A., et al.
Publicado: (2015)

Epidemiology of Cryptococcosis and Cryptococcal Meningitis in a Large Retrospective Cohort of Patients After Solid Organ Transplantation
por: George, Ige A., et al.
Publicado: (2017)

High Burden of Cryptococcal Meningitis Among Antiretroviral Therapy–Experienced Human Immunodeficiency Virus–Infected Patients in Northern Uganda in the Era of “Test and Treat”: Implications for Cryptococcal Screening Programs
por: Okwir, Mark, et al.
Publicado: (2022)

A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2019)

Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance
por: Hope, William, et al.
Publicado: (2019)

Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis
por: Shiri, Tinevimbo, et al.
Publicado: (2020)

An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2021)

Comparative Effectiveness of Induction Therapy for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: A Network Meta-Analysis
por: Campbell, Jeffrey I., et al.
Publicado: (2015)

Therapeutic Lumbar Punctures in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis: Should Opening Pressure Direct Management?
por: Kagimu, Enock, et al.
Publicado: (2022)

Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings
por: Bahr, Nathan C., et al.
Publicado: (2014)

Accuracy of Noninvasive Intraocular Pressure or Optic Nerve Sheath Diameter Measurements for Predicting Elevated Intracranial Pressure in Cryptococcal Meningitis
por: Nabeta, Henry W., et al.
Publicado: (2014)

Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy–Naïve and –Experienced Patients in Sub-Saharan Africa
por: Kalata, Newton, et al.
Publicado: (2021)

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
por: Schaars, CF, et al.
Publicado: (2006)

Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis
por: Molloy, Síle F., et al.
Publicado: (2018)

High Mortality in HIV-Associated Cryptococcal Meningitis Patients Treated With Amphotericin B–Based Therapy Under Routine Care Conditions in Africa
por: Patel, Raju K K, et al.
Publicado: (2018)

Cryptococcal mesenteric lymphadenitis in an immunocompromised host
por: Mardi, Kavita, et al.
Publicado: (2012)

Induction therapy with high‐dose fluconazole plus flucytosine for human immunodeficiency virus‐uninfected cryptococcal meningitis patients: Feasible or not?
por: Zhao, Hua‐Zhen, et al.
Publicado: (2022)

Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study
por: Ingle, Suzanne M, et al.
Publicado: (2023)

C1q Confers Protection Against Cryptococcal Lung Infection by Alleviating Inflammation and Reducing Cryptococcal Virulence
por: Zhao, Xu, et al.
Publicado: (2023)

Baseline Cytomegalovirus Viremia at Cryptococcal Meningitis Diagnosis Is Associated With Long-term Increased Incident TB Disease and Mortality in a Prospective Cohort of Ugandan Adults With HIV
por: Ellis, Jayne, et al.
Publicado: (2023)

Cellular Immune Activation in Cerebrospinal Fluid From Ugandans With Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome
por: Meya, David B., et al.
Publicado: (2015)

2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
por: Chesdachai, Supavit, et al.
Publicado: (2019)

A Prospective Study of Mortality from Cryptococcal Meningitis following Treatment Induction with 1200mg Oral Fluconazole in Blantyre, Malawi
por: Gaskell, Katherine M., et al.
Publicado: (2014)

Atypical Presentation of Pediatric Systemic Lupus Erythematosus Complicated by Cryptococcal Meningitis
por: Hashem, Heba Ezzat, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l57gsh5h5b86n21d6ir1pu9vuf